Clinical bottom line
Anti-interferon therapies represent a promising, targeted approach for patients with refractory systemic lupus erythematosus (SLE) characterized by high interferon (IFN) pathway activity. Current evidence suggests these agents can reduce disease activity and serologic markers in subsets of patients with moderate-to-severe SLE who have inadequate response to conventional immunosuppression. However, clinical benefit varies and long-term safety data remain limited. Careful patient selection based on interferon gene signature profiling may optimize therapeutic outcomes. Anti-IFN therapies warrant consideration as adjuncts in refractory SLE but require further validation in broader clinical practice.
What the evidence shows
SLE pathogenesis is strongly linked to dysregulated type I interferon signaling, particularly interferon-alpha (IFN-α), which promotes immune activation, autoantibody production, and tissue inflammation (Crow et al., 2011; Hagberg et al., 2016). Elevated IFN signatures correlate with disease activity and severity, making the IFN pathway a rational therapeutic target (Daniel et al., 2012).
Several biologics targeting IFN-α or its receptor have been developed and evaluated in clinical trials. For example, anifrolumab, a monoclonal antibody against the type I IFN receptor subunit 1, demonstrated significant reductions in SLE disease activity indices and corticosteroid use in phase 3 trials of moderate-to-severe SLE patients with high IFN gene signatures (Chaichian et al., 2021). These trials showed improvements in skin and joint manifestations and reduced flares compared to placebo, supporting IFN blockade as an effective strategy in selected patients (Mouyis et al., 2016; Lichtman et al., 2012).
Other agents targeting IFN-α directly or downstream signaling pathways have shown variable efficacy, highlighting heterogeneity in patient responses (Misra et al., 2017). Biomarker-driven approaches, such as measuring IFN gene expression profiles, have been proposed to identify patients most likely to benefit (Chaichian et al., 2021). This precision medicine approach is still evolving but may enhance clinical utility.
Caveats and uncertainty
Despite encouraging trial results, several limitations temper enthusiasm for routine anti-IFN therapy use. First, not all patients with SLE exhibit elevated IFN signatures, and those with low IFN activity may derive limited benefit, underscoring the need for reliable biomarkers (Hagberg et al., 2016). Second, long-term safety data are sparse, with concerns about increased risk of infections due to IFN pathway suppression (Lichtman et al., 2012).
Additionally, the heterogeneity of SLE clinical phenotypes and immunopathology complicates generalization of trial findings. Many studies excluded patients with severe organ involvement such as active lupus nephritis or neuropsychiatric lupus, limiting applicability to these subgroups (Chaichian et al., 2021). The optimal timing, dosing, and combination with other immunosuppressants remain to be defined.
Finally, cost and access considerations may restrict widespread adoption of these biologics in clinical practice.
How this may change practice
Anti-interferon therapies offer a novel, mechanism-based option for patients with refractory SLE who have failed standard therapies and exhibit high IFN pathway activity. Incorporating IFN gene signature testing into clinical evaluation could guide personalized treatment decisions, reserving these agents for patients most likely to respond.
Clinicians should weigh potential benefits against infection risks and monitor patients closely. Anti-IFN agents may be integrated as adjuncts to existing immunosuppressive regimens rather than standalone therapies. Ongoing and future studies will clarify their role in severe organ involvement and long-term disease control.
In summary, anti-interferon therapies represent an important advance in SLE management that may improve outcomes in selected refractory cases, but require cautious implementation and further validation.